Interleukin 2-mediated conversion of ovarian cancer-associated CD4 + regulatory T cells into proinflammatory interleukin 17-producing helper T cells

Journal of Immunotherapy

Volumn 32, Issue 2, 2009, Pages 101-108

  Leveque, Lucie ^a   Deknuydt, Florence ^a   Bioley, Gilles ^a   Old, Lloyd J ^b   Matsuzaki, Junko ^c   Odunsi, Kunle ^c   Ayyoub, Maha ^a   Valmori, Danila ^a,d,e  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Team 12   (France)

Author keywords

IL 2; Immune response; Ovarian cancer; T H17; T reg

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM TUMOR; EX VIVO STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; BIOSYNTHESIS; CARCINOMA; DRUG EFFECT; IMMUNOLOGY; METABOLISM; OVARY TUMOR;

CARCINOMA; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; OVARIAN NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63649120341     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318195b59e     Document Type: Article

References (42)

1. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007;25:2873-2883.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-213.
4. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003; 63:6076-6083.
5. + T cells. Clin Cancer Res. 2006;12:398404.
6. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942-949.
7. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102:18538-18543.
8. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol. 2002;2:933-944.
9. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001; 182:18-32.
10. H17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24:677-688.
11. H17 and regulatory T cells. Nature. 2006;441:235-238.
12. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448:484-487.
13. Tartour E, Fossiez F, Joyeux I, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999;59: 3698-3704.
14. Ciree A, Michel L, Camilleri-Broet S, et al. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer. 2004; 112: 113-120.
15. H17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730-6733.
16. Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol. 1997; 15:3399-3407.
17. Kato T, Furumoto H, Ogura T, et al. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun. 2001;282:735-738.
18. + T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000; 60:4499-4506.
19. regs. J Clin Invest. 2005; 115:1953-1962.
20. regs. Clin Immunol. 2008;126: 291-302.
21. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8: 942-949.
22. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005;65:10794-10800.
23. + FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007; 110:2983-2990.
24. H17 cells. J Exp Med. 2007; 204:1849-1861.
25. + regulatory thymocytes because of their responsiveness to different cytokines. Blood. 2004;103:3117-3121.
26. Evans HG, Suddason T, Jackson I, et al. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci USA. 2007; 104:17034-17039.
27. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101: 2620-2627.
28. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 2002;99:2114-2121.
29. Hirahara N, Nio Y, Sasaki S, et al. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology. 2001;61:79-89.
30. H17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res. 2007;67:1 1970-11979.
31. H17-polarized cells eradicate large established melanoma. Blood. 2008;1 12:362-373.
32. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
33. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24: 179-189.
34. Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26:371-381.
35. Gordinier ME, Zhang HZ, Patenia R, et al. Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma. Clin Cancer Res. 1999;5:2498-2505.
36. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother. 2006;55:237-245.
37. Bauge C, Legendre F, Leclercq S, et al. Interleukin-1beta impairment of transforming growth factor beta1 signaling by down-regulation of transforming growth factor beta receptor type II and up-regulation of Smad7 in human articular chondrocytes. Arthritis Rheum. 2007;56:3020-3032.
38. H17 cells in the absence of exogenous TGF-beta. J Immunol. 2007;178:6725-6729.
39. + T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 2007;67:7487-7494.
40. Sereti I, Imamichi H, Natarajan V, et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest. 2005; 115:1839-1847.
41. + regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004;20:107-118.
42. Vence L, Palucka AK, Fay JW, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2007; 104:20884-20889.